Cargando…

Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon

BACKGROUND: Increased access to HIV testing is essential in working towards universal access to HIV prevention and treatment in resource-limited countries. We here evaluated currently used HIV diagnostic tests and algorithms in Cameroon for their ability to correctly identify HIV infections. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghokeng, Avelin F., Mpoudi-Ngole, Eitel, Dimodi, Henriette, Atem-Tambe, Arrah, Tongo, Marcel, Butel, Christelle, Delaporte, Eric, Peeters, Martine
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768789/
https://www.ncbi.nlm.nih.gov/pubmed/19893738
http://dx.doi.org/10.1371/journal.pone.0007702
_version_ 1782173510015123456
author Aghokeng, Avelin F.
Mpoudi-Ngole, Eitel
Dimodi, Henriette
Atem-Tambe, Arrah
Tongo, Marcel
Butel, Christelle
Delaporte, Eric
Peeters, Martine
author_facet Aghokeng, Avelin F.
Mpoudi-Ngole, Eitel
Dimodi, Henriette
Atem-Tambe, Arrah
Tongo, Marcel
Butel, Christelle
Delaporte, Eric
Peeters, Martine
author_sort Aghokeng, Avelin F.
collection PubMed
description BACKGROUND: Increased access to HIV testing is essential in working towards universal access to HIV prevention and treatment in resource-limited countries. We here evaluated currently used HIV diagnostic tests and algorithms in Cameroon for their ability to correctly identify HIV infections. METHODS: We estimated sensitivity, specificity, and positive and negative predictive values of 5 rapid/simple tests, of which 3 were used by the national program, and 2 fourth generation ELISAs. The reference panel included 500 locally collected samples; 187 HIV -1 M, 10 HIV-1 O, 259 HIV negative and 44 HIV indeterminate plasmas. RESULTS: None of the 5 rapid assays and only 1 ELISA reached the current WHO/UNAIDS recommendations on performance of HIV tests of at least 99% sensitivity and 98% specificity. Overall, sensitivities ranged between 94.1% and 100%, while specificities were 88.0% to 98.8%. The combination of all assays generated up to 9% of samples with indeterminate HIV status, because they reacted discordantly with at least one of the different tests. Including HIV indeterminate samples in test efficiency calculations significantly decreased specificities to a range from 77.9% to 98.0%. Finally, two rapid assays failed to detect all HIV-1 group O variants tested, with one rapid test detecting only 2 out of 10 group O specimens. CONCLUSION: In the era of ART scaling-up in Africa, significant proportions of false positive but also false negative results are still observed with HIV screening tests commonly used in Africa, resulting in inadequate treatment and prevention strategies. Depending on tests or algorithms used, up to 6% of HIV-1 M and 80% of HIV-1 O infected patients in Cameroon do not receive ART and adequate counseling to prevent further transmission due to low sensitivities. Also, the use of tests with low specificities could imply inclusion of up to 12% HIV negative people in ART programs and increase budgets in addition to inconveniences caused to patients.
format Text
id pubmed-2768789
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-27687892009-11-06 Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon Aghokeng, Avelin F. Mpoudi-Ngole, Eitel Dimodi, Henriette Atem-Tambe, Arrah Tongo, Marcel Butel, Christelle Delaporte, Eric Peeters, Martine PLoS One Research Article BACKGROUND: Increased access to HIV testing is essential in working towards universal access to HIV prevention and treatment in resource-limited countries. We here evaluated currently used HIV diagnostic tests and algorithms in Cameroon for their ability to correctly identify HIV infections. METHODS: We estimated sensitivity, specificity, and positive and negative predictive values of 5 rapid/simple tests, of which 3 were used by the national program, and 2 fourth generation ELISAs. The reference panel included 500 locally collected samples; 187 HIV -1 M, 10 HIV-1 O, 259 HIV negative and 44 HIV indeterminate plasmas. RESULTS: None of the 5 rapid assays and only 1 ELISA reached the current WHO/UNAIDS recommendations on performance of HIV tests of at least 99% sensitivity and 98% specificity. Overall, sensitivities ranged between 94.1% and 100%, while specificities were 88.0% to 98.8%. The combination of all assays generated up to 9% of samples with indeterminate HIV status, because they reacted discordantly with at least one of the different tests. Including HIV indeterminate samples in test efficiency calculations significantly decreased specificities to a range from 77.9% to 98.0%. Finally, two rapid assays failed to detect all HIV-1 group O variants tested, with one rapid test detecting only 2 out of 10 group O specimens. CONCLUSION: In the era of ART scaling-up in Africa, significant proportions of false positive but also false negative results are still observed with HIV screening tests commonly used in Africa, resulting in inadequate treatment and prevention strategies. Depending on tests or algorithms used, up to 6% of HIV-1 M and 80% of HIV-1 O infected patients in Cameroon do not receive ART and adequate counseling to prevent further transmission due to low sensitivities. Also, the use of tests with low specificities could imply inclusion of up to 12% HIV negative people in ART programs and increase budgets in addition to inconveniences caused to patients. Public Library of Science 2009-11-06 /pmc/articles/PMC2768789/ /pubmed/19893738 http://dx.doi.org/10.1371/journal.pone.0007702 Text en Aghokeng et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Aghokeng, Avelin F.
Mpoudi-Ngole, Eitel
Dimodi, Henriette
Atem-Tambe, Arrah
Tongo, Marcel
Butel, Christelle
Delaporte, Eric
Peeters, Martine
Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon
title Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon
title_full Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon
title_fullStr Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon
title_full_unstemmed Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon
title_short Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon
title_sort inaccurate diagnosis of hiv-1 group m and o is a key challenge for ongoing universal access to antiretroviral treatment and hiv prevention in cameroon
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768789/
https://www.ncbi.nlm.nih.gov/pubmed/19893738
http://dx.doi.org/10.1371/journal.pone.0007702
work_keys_str_mv AT aghokengavelinf inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT mpoudingoleeitel inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT dimodihenriette inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT atemtambearrah inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT tongomarcel inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT butelchristelle inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT delaporteeric inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon
AT peetersmartine inaccuratediagnosisofhiv1groupmandoisakeychallengeforongoinguniversalaccesstoantiretroviraltreatmentandhivpreventionincameroon